European Cystic Fibrosis Society

Tuesday 9 June 2009

Physiotherapy Short Course - Management of Infants with Cystic Fibrosis - (1^1/2 days course)
9 June: 08:30 - 1700
10 June 08:30 - 12:30
Further information here

9 June: 08:30-17:30 - ECFS Board Meeting

Wednesday 10 June 2009

Exhibition Build-up
Pre-Conference Meetings - For more information of the meetings listed below, click here for more details
- CF Europe Meetings
- ECFS Clinical Trials Network Meeting
- ECFS Diagnostics Working Group Meeting
- ECFS Neonatal Screening Working Group Meeting
- ECFS Registry Meeting - Moved to 11 June, 18:15-19:15
- European CF Nutrition Group Meeting
- International Physiotherapy Group Annual General Assembly & Case Presentations
- International Nurse Specialist Group/CF (INSG/CF) Meeting
- Psychosocial Special Interest Group Meeting
- Joint Psychosocial Special Interest Group/International Nurse Specialist Group/CF Meeting

17:00:18:00 - ECFS Annual General Assembly (all ECFS Members are encouraged to attend)
18:30:21:30 - Opening Ceremony and Welcome Reception

Thursday 11 June 2009

08:30- 10:00 - Plenary I - CFTR: 20th Anniversary Celebration
Moderators: S. Elborn (UK) / C. Férec (FR)
Speakers:
Lap Chee Tsui (HK)
J. Riordan (US)
B. Kerem (IL) 

10:00:10:30 - Coffee Break

10:30- 12:00 - Symposium 1 - Grand Rounds in Pulmonary Disease (case presentations)
Expert Panel:
S. Bell (AU), B. Fauroux (FR), H. Heijerman (NL), D. Bilton (UK), G. Taccetti (IT)

10:30-10:45 - Abstract 277: Lung transplantation in patients with cystic fibrosis and mycobactrium abscessus infection - M. Gilljam (SE)
10:45-11:00 - Abstract 275: Infection by Nocardia farcinica in CF - M. Roussey (FR)
11:00-11:15 - Abstract 276: First colonisation with P. aeruginosa - only detected in the upper airways - eradicated with sinonasal inhalation of Tobramycin - J. Mainz (DE)
11:15-11:30 - A pain in the neck - J. Greenwood (UK)
11:30-11:45 - Bilateral hilar lymphadenopathy in cystic fibrosis (CF) - when is it significant? - F. Perrin (UK)
11:45-12:00 - Aspergillus paraspinal abcess after lung transplantation in a teenage CF patient - P. Seddon (UK)
Best Case Presentation Award by the Expert Panel

10:30-12:00 - Symposium 2 - Designing the Optimum CF Microbiology Service
Moderators: R. Canton (SP) / M. Denton (UK)
Speakers:
10:30-10:52 - What is expected from the clinical viewpoint? - D. Peckham (UK)
10:52-11:14 - Detection and identification of CF pathogens - P. Plésiat (FR)
11:14-11:36 - Susceptibiltiy testing: when, how and how frequently? - S. Aaron (CA)
11:36-12:00 - Gentotyping and epidemiology - E. Mahenthiralingam (UK)

10:30-12:00 - Symposium 3 - Nutritional Challenges across the Lifespan
Moderators: F. Hollander (NL) / A. Morton (UK)
Speakers:
10:30-10:52 - Nutritional Management of Infants – A. Munck (FR)
10:52-11:14 - Body Image, Disordered Eating and Psychosocial Aspects of Eating – A. Quittner (US)
11:14-11:36 - Nutritional Challenges in Pregnancy – A. Morton (UK)
11:36-12:00 - Nutrition in the Pre and Post-Transplant Patient – D. Kalnins (CA)

10:30-12:00 - Symposium 4 - Mutation Specific Therapies 2009
Moderators: G. Bellon (FR) / J. Riordan (US)
Speakers:
10:30-10:52 - Mutation specific therapies PTC 124 – E. Kerem (IL)
10:52-11:14 - Mutation therapy Miglustat - F. Becq (FR)
11:14-11:36 - Challenges and Opportunities for Development of CFTR Modulators - C. Ordonez (US)
11:36-12:00 - Natural drugs for splicing - B. Kerem (IL)

10:30 - 12:00 - Syposium 5 - Cystic Fibrosis in the Family
Moderators: A. Gravelle (CA) / J. de Vries (NL)
Speakers:
10:30-10:52 - Involving young children in their care – V. David (FR)
10:52-11:14 - Coping with the transition from childhood to adulthood - M. Bryon (UK)
11:14-11:36 - Well siblings – T. Havermans (BE)
11:35-12:00 - Parents and partners: Challenges for the future - M. van Hattem (NL)

12:00-14:30 Lunch
12:30-14:00 - Gilead Satellite Symposium

Guidance on cystic fibrosis treatment – is it time to give the patient more responsibility?

12:30-14:00 - Satellite Symposium
Genetic testing: the challenges labs and clincians face in CF Diagnosis

12:15-14:15 - EuroCareCF/ECFS Registry Steering Committee Meeting
13:30-14:30 - Guided Poster tours
13:30-14:30 - CF Aging Group Meeting

14:30-16:00 - Workshop 1 - Educational Issues
Moderators: J. de Vries (NL) / L. Goldbeck (DE)
14:30-14:48 - Abstract 386: Provding inpatient education on a segregated ward - J. Steel (UK)
14:48-15:06 - Abstract 396: Pedagogic drivers in therapeutic education for patients with Cystic Fibrosis - C. Berville (FR)
15:06-15:24 - Abstract 388: Experience of parents of CF pre-teenagers participating in a therapeutic education programme - V. Varlet (FR)
15:24-15:42 - Abstract 395: European survey on schooling of children, teenagers and young adults with cystic fibrosis - I. Sermet (EUR)
15:42-16:00 - Abstract 410: How we managed to improve a professional attitude in the nursing team to deal with topics of sexuality, fertility and reproduction in relation to CF patients - M. van Hattem (NL)

14:30-16:00 - Workshop 2 - CFTR and Cell Biology
Moderators: M. Amaral (PT) / A. Edelman (FR)
14:30-14:45 - Overview: M. Amaral (PT)
14:45-15:00 - Abstract 71: COMMD1 promotes CFTR trafficking through inhibition of ubiquitination - L. Drévillon (FR)
15:00-15:15 - Abstract 70: Correction of the F508del-CFTR function by the Gonadotropin-Releasing hormone (GnRH) in polarized and non-polarized epithelial cells - N. Benz (FR)
15:15-15:30 - Abstract 92: Mitochondrial glutathione and decreased complex I activity in cystic fibrosis models - M. Kelly (FR) 
15:30-15:45 - Abstract 68: Rescue of A455E CFTR by temperature, small molecule correctors and transcomplementation – L. Cebotaru (US)
15:45-16:00 - Abstract 115: New targeting method for nucleic acid transfer into the lung – F. Beilvert (FR)

14:30-16:00 -  Workshop 3 - Gastrointestinal and Nutritional Issues
Moderators: F. Huet (FR) / H. Mc Cabe (UK)
14:30-14:45 - Abstract 330: Proof of principle. Treatment of cystic fibrosis-related diabetes: a possible role for complementary metformin? – J. van den Berg (NL)
14:45-15:00 - Abstract 334: Autonomic Neuropathy in Cystic Fibrosis – A. Palamarthy (UK)
15:00-15:15 - Abstract 338: Mineral bone density in children and bone status of adults with cystic fibrosis – E. Colin (FR)
15:15-15:30 - Abstract 315: Gallbladder dysfunction contributes to impaired bile salt homeostasis in cystic fibrosis – D. Debray (FR)
15:30-15:45 - Abstract 316: Detection of bile acids in sputum as a screening method for assessment of aspiration of duodenogastric contents in patients with cystic fibrosis – A. Pauwels (BE)
15:45-16:00 - Abstract 319: Immuno-Reactive Trypsine and extern pancreatic status in cystic fibrosis children – E. Chaillou (FR)

14:30-16:00 - Workshop 4 - Pathogenesis and Modulation of Lung Inflammation
Moderators: T. Wagner (DE) / R. Bals (DE)
14:30-14:45 - Abstract 218: Azithromycin is not able to decrease inflammatory process in cystic fibrosis human bronchial epithelial cells – V. Saint-Criq (FR)
14:45-15:00 - Abstract 219: Weak anti-inflammatory effects of glucocorticoids on CF bronchial epithelial cells – C. Rebeyrol (FR)
15:00-15:15 - Abstract 209: Comparison of Inflammatory responses to Pseudomonas aeruginosa Lipopolysaccharide isolates compared to Staphylococcus aureus Peptidoglycan – P. Buchanan (UK)
15:15-15:30 - Abstract 220: IP-10 induction after LPS stimulation is compromised in cystic fibrosis bronchial epithelial cells – M. Henke (DE)
15:30-15:45 - Abstract 203: Anoxia prolongs the life and functionality of polymorphonuclear leukocytes – P.Ø. Jensen (DK)
15:45-16:00 - Abstract 221: Drug specific T cells in patients with a history of non-immediate hypersensitivity reactions – P. Whitaker (UK)

14:30-16:00 -  Workshop 5 - The New Therapies' Pipeline
Moderators: M. Mall (DE) / A. Smyth (UK)
14:30-14:45 - Abstract 67: Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 – F. Van Goor (US)
14:45-15:00 - Abstract 97: Final results of a 14- and 28-day study of VX-770 in subjects with CF – F. Accurso (US)
15:00-15:15 - Abstract 98: Pharmacological characterization of a novel water-soluble activator of F508del-CFTR – J. Bertrand (FR)
15:15-15:30 - Abstract 102: The novel long acting ENaC blocker P643 has therapeutic effects in chronic cystic fibrosis-like lung disease in mice – Z. Zhou (DE)
15:30-15:45 - Abstract 116: Variations on hydrophobic domains in Lipophosphoramidates results in lung transfection’s improvement and lower toxicity – T. Montier (FR)
15:45-16:00 - Abstract 117: Histidinylated linear PEIs as new DNA carriers for in vitro and in vivo gene transfer with low toxicity – P. Guégan (FR)

14:30-16:00 - Oral Poster Session I - Infection and Inflammation
Moderators: M. Denton (UK) / M. Fayon (FR)
14:30-14:40 - Abstract 130: Change in composition and structure of bacteria in the CF airway over one year – F.A. Stressmann (UK)
14:40-14:50 - Abstract 149: Monitoring of the Initial Pseudomonas aeruginosa Colonization in Cystic Fibrosis Patients Demonstrated High Clonal Diversity – A. Fernández-Olmos (SP)
14:50-15:00 - Abstract 156: Genotype based evaluation of eradication treatment of new P. aeruginosa infections in CF patients – F. De Baets (BE)
15:00-15:10 - Abstract 255: Dynamics of upper and lower airway colonisation with P. aeruginosa and S. aureus in CF-patients within 3.5 years – J. Mainz (DE)
15:10-15:20 - Abstract 252: Cytokine pattern in broncho-alveolar lavage in children with Cystic Fibrosis and infection with Pseudomonas aeruginosa – T. Frischer (AT)
15:20-15:30 - Abstract 152: Genotyping of Pseudomonas aeruginosa isolates from aquatic environment at a Swedish hospital and relation to infection of lung transplanted patients with Pseudomonas – E. Johansson (SE)
15:30-15:40 - Abstract 89: Long acting β2-agonist and corticosteroid restore airway glandular cell functionality altered by Staphylococcus aureus virulence factors – J.M. Zahm (FR)
15:40-15:50 - Abstract 169: Community-Acquired MRSA causes earlier infection than Hospital-Acquired MRSA in patients with cystic fibrosis – S. Campana (IT)
15:50-16:00 - Abstract 139: In vitro activity of tigecycline and other antibiotics against Burkholderia cepacia complex (Bcc) and other cystic fibrosis (CF)-associated Gram negative bacteria – M. Denton (UK)

16:00:16:30 - Coffee Break

16:30-18:00 - Workshop 6 - Genetics: Science and Practice 
Moderators: C. Castellani (IT) / G. Cutting (US)
Speakers:
16:30-16:52 - Molecular tools for the diagnosis of CF and CFTR related disorders: what clinicians should know - M. Goossens (FR)
16:52-17:07 - Abstract 14 - Comprehensive analysis of the French NBS cohort: Excellent mutation detection rate despite high allelic heterogeneity - M. des Georges (FR)
17:07-17:22 - Abstract 3 - ETR-3 is a major regulator of CFTR pre-mRNA splicing - G. Dujardin (FR)
17:22-17:37 - Abstract 15 - In vivo and in vitro effect of E831X mutation - A. Hinzpeter (FR)
17:37-18:00 - CFTR2 2009 Genotype/phenotype correlations for the clinician - G. Cutting (US)

16:30-18:00 - Workshop 7 - Bacterial Pathogen Identification and Susceptibility Testing: Lessons to be Learned
Moderators: B. Tümmler (DE) / C. Segonds (FR)
16:30-16:45 - Introduction: Changing challenges of the microbiology of the CF lung - D. Worlitzsch (DE)
16:45-17:00 - Abstract 132: EuroCareCF European Microbiology Quality Assurance Trials - B. Tümmler (DE)
17:00-17:15 - Poster 142: Low rates of Pseudomonas aeruginosa (Pa) misidentification in Australian cystic fibrosis (CF) patients - S. Bell (AU)
17:15-17:30 - Abstract 163 - Colistin sulfate/tobramycin combination is superior for killing biofilm P. aeruginosa than monotherapy in vitro - G. Harmann (DE)
17:30-17:45 - Abstract 164: Resistance in cystic fibrosis Pseudomonas aeruginosa strains is not mediated by common acquired antibiotic resistance genes - D. De Vos (BE)
17:45-18:00 - Abstract 181: Impact of strict anaerobes on the pathogenesis of lung infection in patients with cystic fibrosis - M. Ulrich (DE)

16:30-18:00 - Workshop 8 - Inhalation and Adjuncts to Physiotherapy
Moderators: L. Lannefors (SE) / C. Lejosne (FR)
16:30-16:45 - Introduction: L. Lannefors (SE)
16:45-17:00 - Abstract 298: A randomised, cross-over trial of upright sitting versus alternate side lying during nebulised delivery of medication in cystic fibrosis – R. Dentice (AU)
17:00-17:15 - Abstract 305: PTs'role in the caring of CF patients in France in 2009 – C. Lejosne (FR)
17:15-17:30 - Abstract 264: Lung delivery of a new tobramycin nebuliser solution (150mg/1.5 ml) by an investigational eFlow^® nebuliser is equivalent to TOBI^® but in a fraction of time – A. Coates (CA)
17:30-17:45 - Abstract 265: Preclinical study of a new antibiotic for nebulisation – L. Vecellio (FR)
17:45-18:00 - Abstract 297: The use of NIV within a regional adult Cystic Fibrosis Centre – J. Barrett (UK)

16:30-18:00 - Workshop 9 - Epithelial Injury and Repair
Moderators: S. Randell (US) / M. Chanson (CH)
16:30-16:45 - Stem cell injury and repair - S. Randell (US)
16:45-17:00 - Abstract 90: Are basal cells progenitors of the human bronchiolar epithelium? – T. Jolly (FR)
17:00-17:15 - Abstract 91: Epithelial factors produced during the remodelling of the human airway epithelium – J. Roux (FR)
17:15-17:30 - Abstract 75: Connexin 26 is implied in the regulation of airway epithelium repair – S. Crespin (CH)
17:30-17:45 - Abstract 222: Cytokine production in the differentiating human airway epithelium – M. Chanson (CH)
17:45-18:00 - Abstract 225: Decreased expression of Nod2-receptors in cystic fibrosis airway epithelial cells- G. Roomans (SE)

16:30-18:00 - Workshop 10 - Motivation and Attitude to Treatment
Moderators: T. Havermans (BE) / M. Braithwaite (AU) 
16:30-16:48 - Abstract 374: Improving self efficacy in adolescents and young adults with cystic fibrosis (CF) – J. Cheney (AU)
16:48-17:06 - Abstract 373: Non-adherence as coping strategy of young adult patients with CF. A qualitative study – G. Seitz (DE)
17:06-17:24 - Abstract 368: Self-care: a qualitative study of adults with CF – D. Greenop (UK)
17:24-17:42 - Abstract 371: Exploration of personality, psychosocial factors and illness effect on adherence behaviour in CF – M. Braithwaite (AU)
17:42-18:00 - Abstract 398: Quality of Care and Quality of Life: Patient/Healthcare Perspectives – S. Armoni (IL)

16:30-18:00 - Oral Poster Session II - Clinical Care
Moderators: M. Ballmann (DE) / C. Haworth (UK)
16:30-16:40 - Abstract 146: Paranasal sinuses are a focus for P. aeruginosa (PA) lung infection in CF – H. Johansen (DK)
16:40-16:50 - Abstract 100: Effects of denufosol on sinusitis-related complaints in a phase 3 trial in cystic fibrosis patients – A. Mospan (US)
16:50-17:00 - Abstract 242: Respiratory exacerbations in children aged 0-3 years in the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study – C. Byrnes (AU)
17:00-17:10 - Abstract 243: Pre-flight evaluation of adult patients with cystic fibrosis – B. Skrede (NO)
17:10-17:20 - Abstract 88: Airway epithelial responses to hypertonic solutions: different in vivo responses in CF and non-CF human subjects – P. Middleton (AU)
17:20-17:30 - Abstract 448: Prevalence of renal impairment in children with cystic fibrosis (CF) – M. Fayon (FR)
17:30-17:40 - Abstract 333: Characteristics of visual function in adults with cystic fibrosis – K. Evans (UK)
17:40-17:50 - Abstract 346: The experience of using megestrol acetate (MA) in a large UK adult CF centre – J. Barrett (UK)
17:50-18:00 - Abstract 310: Outcome in Cystic Fibrosis Liver Disease – M. Rowland (IE)                  

18:15-19:15 - European CF Registry Meeting:
Update on progress towards data collection, registry reports and common software
18-15-19:30 - CTN Standardisation Committee Meeting

Back to top

Friday 12 June 2009 

07:15-08:15 - Round Tables
07:30-08:30 - Journal of CF Editorial Board
08:30-10:00 - Depression Study Group

08:30-10:00 - Symposium 6 - Clinical Trials
Moderators: K. De Boeck (BE) / A. Reimann (DE)
Speakers:
08:30-18:52 - A UK CF Gene Therapy Consortium - E. Alton (UK)
08:52-09:14 - New Drugs: add on or replace? (Burden of therapy, design, regulatory) - C. Goss (US)
09:14-09:36 - Clincial Research: bringing drugs and patients together - S. Elborn (UK)
09:36-10:00 - ECFS Clinical Trials Network - K. De Boeck (BE)

08:30-10:00 - Symposium 7 - Advances in Genetics and Screening
Moderators: C. Férec (FR) / M. Stuhrmann (DE)
Speakers:
08:30-08:52 - Carrier screening: ECFS recommendations - M. Macek (CZ)
08:52-09:14 - Newborn screening, benefits, methods of screening - C. Castellani (IT)
09:14-09:36 - CFTR related disorders - C. Férec (FR)
09:36-10:00 - North American modifiers gene study - J. Zielenski (CA) / S. Blackman (US)

08:30-10:00 - Symposium 8 - Pulmonology: Pro/Con Debates
Moderators: J. Davies (UK) / S. Bell (AU)
Debate 1 - CF lung disease: inflammation comes first
08:30-08:47 - Pro: M. Fayon (FR)
08:47-09:04 - Con: C. Wainwright (AU)
09:04-09:15 - Discussion
Debate 2 - Patients with pan resistant micro-organisms should not be transplanted
09:15-09:32 - Pro: P. Noone (US)
09:32-09:49 - Con: R. Souilamas (FR)
09:49-10:00 - Discussion 

08:30-10:00 - Symposium 9 - Physiotherapy Management at the ends of the spectrum in CF
Moderators: M. McIlwaine (CA) / H. Gauchez (FR)
Speakers:
08:30-08:52 - Management of well infants diagnosed with newborn screening - A. Prasad (UK)
08:52-09:14 - Management of children with respiratory symptoms - M. McIlwaine (CA)
09:14-09:36 - Management of the adult with normal lung function - J. Bradley (UK)
09:36-10:00 - Management of the adult in acute respiratory failure - B. Button (AU)

08:30-10:00 - Symposium 10 - Bone Health in CF
Moderators: C. Haworth (UK) / I. Sermet-Gaudelus (FR)
Speakers:
08:30-08:52 - Body composition and assessment of bone health - M.L. Bianchi (IT)
08:52-09:14 - Aetiology of bone disease - I. Sermet-Gaudelus (FR)
09:14-09:36 - Nutritional aspects of bone disease - S. Wolfe (UK)
09:36-10:00 - Reduced bone mineral density: which therapeutic options? - C. Haworth (UK)

10:00-10:30 - Coffee Break

10:30-12:00 - Symposium 11 - Improving Data Quality of the European Registry
Moderators: S. Ravilly (FR) / H. Olesen (DK)
Speakers:
10:30-10:52 - Z-score and nutrition - B. Wiedermann (DE)
10:52-11:14 - Survival analysis - V. Scotet (FR)
11:14-11:36 - FEV1 percentile - K. De Boeck (BE)
11:36-12:00 - Most recent update - H. Olesen (DK)

10:30-12:00 - Symposium 12 - Tools for Translational CFTR Research
Moderators: B. Scholte (NL) / C. Coraux (FR)
Speakers:
10:30-10:52 - New animal models - D. Stoltz (US)
10:52-11:14 - Lessons from mice - H. de Jonge (NL)
11:14-11:36 - ENaC Over-expressing mice - M. Mall (DE)
11:36-12:00 - In Vitro use of primary cells - C. Coraux (FR)

10:30-12:00 - Symposium 13 - Monitoring Lung Disease
Moderators: H. Hebestreit (DE) / B. Fauroux (FR)
Speakers:
10:30-10:52 - Monitoring lung disease in young non sputum producing children - C. Van der Ent (NL)
10:52-11:14 - Lung function and exercise tolerance - H. Hebestreit (DE)
11:14-11:36 - BAL and breath condensate - F. Ratjen (CA)
11:36-12:00 - NIV: When to start and when to stop? - B. Fauroux (FR)

10:30-12:00 - Symposium 14 - Prevention and Treatment of Lung Infections
Moderators: P. Drevinek (CZ) / G. Chabanon (FR)
Speakers:
10-30-10:52 - Can we prevent acquisition of CF pathogens from the environment? - C. Moser (DK)
10:52-11:14 - Should we treat anaerobes and microaerophiles? - D. Worlitszch (DE)
11:14-11:36 - Antibiotic prophylaxis in CF: What do we do now? - A. Smyth (UK)
11:36-12:00 - First infection with P. aeruginosa: Diagnosis, monitoring and therapy - T. Pressler (DK)

10:30-12:00 - Symposium 15 - Life after Transplant
Moderators: S. Madge (UK) / C. Cracowski (FR)
Speakers:
10:30-10:52 - Is there an opportunity to say "No"? - K. Dack (UK)
10:52-11:14 - Quality of life before and after transplant - T. Lunnon-Wood (UK)
11:14-11:36 - Pregnancy after transplant - A. Tsang (CA)
11:36-12:00 - End stage management following transplant - F. Finlayson (AU)

10:30-12:00 - Oral Poster Session III - Genetics and CFTR
Moderators: H. Cuppens (BE) / M. Macek (CZ)
10:30-10:40 - Abstract 1: New putative cis-acting regulatory variations in the CFTR gene – V. Viart (FR)
10:40-10:50 - Abstract 7: The French CF Laboratory Network: seven years experience – E. Girodon (FR)
10:50-11:00 - Abstract 55: Identification of CFTR rearrangements by a CGH locus specific array – S. Quéméner (FR)
11:00-11:10 - Abstract 80: Proteomic analysis of G551D and R117H-CFTR associated proteins – L. Teng (FR)
11:10-11:20  - Abstract 22: Clinical phenotype for the G551D mutation – D. Comer (UK)
11:20-11:30 - Abstract 86: Functional Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in human monocytes – P. Melotti (IT)
11:30-11:40 - Abstract 77: CFTR and Tight Junctions in Cultured Bronchial Epithelial Cells – H. Nilsson (SE)
11:40-11:50 - Abstract 8: Complete sequencing of the CFTR gene using new generation GS-FLX sequencing technology – H. Cuppens (BE)
11:50-12:00 - Abstract 99: Roscovitine : a novel corrector for the functional rescue of F508del-CFTR protein – C. Norez (FR)

12:00-14:30 - Lunch
12:30-14:00 - Roche Satellite symposium
Living Longer with CF  - For the programme please click here 

12:30-14:30 - EuroCareCF WP3 / CFTR-RD Meeting
13:30-14:30 - Guided Poster tours 

14:30-16:00 - Workshop 11 - From Recognising Early Lung Damage to Optimisation of Transplantation in CF Lung Disease
Moderators: S. Elborn (UK) / H. Heijerman (NL)
14:30-14:45 - Abstract 273: CT-detected early structural lung disease is progressive in infants and preschool children – L. Mott (AU)
14:45-15:00 - Abstract 272: Bronchiectasis (BE) on CT is a strong predictor of respiratory tract exacerbations in children with CF – M. Loeve (NL)
15:00-15:15 - Abstract 157: Interim outcomes of a Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study – C. Wainwright (AU)
15:15-15:30 - Abstract 256: Synchronisation of intravenous (IV) antibiotic and in vitro susceptibility of sputum Pseudomonas aeruginosa (PA) does not influence outcome of care of adult CF patients - a prospective study – I. Sequeiros (UK)
15:30-15:45 - Abstract 250: Lactate as a non-invasive marker of CF lung inflammation – T. Bensel (DE)
15:45-16:00 - Abstract 271: Superiority of ATG induction therapy in lung transplant recipients with cystic fibrosis – P. Jaksch (AT)

14:30-16:00 - Workshop 12 - GI Case Presentations
Expert Panel:
J. Sarles (FR) / M. Stern (DE) / M. Cipolli (IT) / J. Walkowiak (PL) / A. Morton (UK)
14:30-14:41 - Cutaneous manifestations as a rare initial presentation of cystic fibrosis – G. Hafen (CH)
14:41-14:52 - Renal Amyloidosis Complicating Cystic Fibrosis – L. Bober (UA)
14:52-15:03 - A rare cause of abdominal pain in an adolescent girl – D. Tjesic-D (HR)
15:03-15:14 - Recurrent abdominal pain: a lesson for adult physicians – N. Simmonds (UK)
15:14-15:25 - Gastrocutaneous Fistula After The Removal Of The Gastrostomy Tube – A. Palamarthy (UK)
15:25-15:36 - Hemodynamic significance of paraumbilical vein in portal hypertension in cystic fibrosis patient – I. Asherova (RU)
15:36-15:47 - Twin sisters with similar, severe, gastrointestinal symptoms – G. Goncalves (PT)
15:47-15:58 - Psoriatic arthritis and recurrent pancreatitis in a young boy with cystic fibrosis: a case report – E. Hatziagorou (GR)
15:58-16:00 - Best Case Presentation Award by Panel

14:30-16:00 - Workshop 13 - Ion Transport and Inflammation
Moderators: O. Zegarra-Moran (IT) / P. Barbry (FR)
14:30-14:45 - Overview: O. Zegarra-Moran (IT)
14:45-15:00 - Abstract 87: The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils – R. Bals (DE)
15:00-15:15 - Abstract 74: Agonists of peroxisome proliferator activated receptor gamma (PPARγ) modulate transepithelial anion secretion in human bronchial epithelial cells – M. Duszyck (US)
15:15-15:30 - Abstract 76: Connexin channels mediate PGE2-dependent regulation of CFTR activity in Calu-3 cells – D. Losa (CH)
15:30-15:45 - Abstract 216: Allergic inflammation produces a hypersecretory airway ion transport phenotype in mice – P. Anagnostopoulou (DE)
15:45-16:00 - Abstract 217: Accumulation of NKT cells in tissues of cystic fibrosis mice – N. Siegmann (DE)

14:30-16:00 - Workshop 14 - Identification of Best Practices
Moderators: C. Colombo (IT) / A. Mehta (UK)
14:30-14:45 - What patients want to know - experience from ECORN-CF - T. Wagner (DE)
14:45-15:00 - Abstract 416: Changes in Cystic Fibrosis mortality and persisting gender inequalities in Australia: 1979 – 2005 – D. Reid (AU)
15:00-15:15 - Abstract 424: UMD-CFTR: a database dedicated to CF and CFTR-related diseases – C. Bareil (FR)
15:15-15:30 - Abstract 415: International benchmarking for cystic fibrosis patient outcomes using registry data – G. Sims (AU)
15:30-15:45 - Abstract 419: Criteria for diagnosis of CF in the French Registry – L. Lemonnier (FR)
15:45-16:00 - Abstract 439: Implementation, uptake and impact of a cystic fibrosis electronic patient record system – D. Peckham (UK)

14:30-16:00 - Workshop 15 - New trends in Physiotherapy
Moderators: L. Smolikova (CZ) / B. Borel (FR)
14:30-14:45 - Introduction: L. Smolikova (CZ)
14:45-15:00 - Abstract 280: Validation of the MST-25: an extension of the modified shuttle test (MST) – M. Elkins (AU)
15:00-15:15 - Abstract 281: Mathematical modelling of oxygen uptake during recovery from exercise – D. Stevens (UK)
15:15-15:30 - Abstract 282: Desaturation on 3-minute step test is associated with impaired outcomes at 12 months in adults with cystic fibrosis - B. Button (AU)
15:30-15:45 - Abstract 293: Better satisfaction of cystic fibrosis paediatric patients with autogenic drainage associated to exercise compared to conventional chest physiotherapy – P. Reix (FR)
15:45-16:00 - Abstract 289: Respiratory exacerbations and muscle strength in adult patients with cystic fibrosis – B. Vrijsen (BE)

16:00-16:30 - Coffee Break

16:30-18:15 - Workshop 16 - Late Breaking Science
Moderators: M. Gray (UK) / F. Dufour (FR)
16:30-16:55 - Overview of ECFS Basic Science Conference 2009 - M. Gray (UK)
16:55-17:20 - TMEM16A as a novel candidate for the Calcium-activated Chloride Channel (CaCC) in CF airways - possible implications for new therapeutic strategies – L. Galietta (IT)
17:20-17:45 - Estrogen-mediated inhibition of CaCC - could this explain the gender gap in CF? – R. Coakley (US)
17:45-18:00 - Abstract 78: PDZ protein interaction: the missing link between CFTR and mucins – T. Pelaseyed (SE)
18:00-18:15 - Abstract 118: The Adenovirus chimeric vector Ad5F35/GFP-CFTR efficiently restores the CFTR deficiency in human airway epithelia via apical surface transduction.- G Gonzalez (FR)

16:30-18:00 - Workshop 17 - Clinical Trials in CF lung disease
Moderators: H. Tiddens (NL) / D. Bilton (UK)
16:30-16:45 - Abstract 105: Effective treatment of chronic Pseudomonas aeruginosa (Pa) infection with tobramycin inhalation powder in CF patients – M. Konstan (US)
16:45-17:00 - Abstract 107: Effect of multiple courses of Aztreonam Lysine for Inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Analysis of 18 month data from CP-AI-006 – G. Retsch-Bogart (US)
17:00-17:15 - Abstract 114: Activity of liposomal formulations on sputum isolated from CF Patients – A. Omri (CA)
17:15-17:30 - Abstract 96: Safety/Efficacy of Inhaled Human Alpha-1 Antitrypsin (AAT) in CF: A Phase II Clinical Study – N. Tov (IL)
17:30-17:45 - Abstract 101: Relationship between pulmonary exacerbations and lung function decline in a six month trial of denufosol – F. Accurso (US)
17:45-18:00 - Abstract 95: Randomised, double blind, placebo-controlled Phase III Study of Bronchitol (inhaled dry powder mannitol) in Cystic Fibrosis (CF) – D. Bilton (UK)

16:30-18:00 - Workshop 18 - Implementation of Screening Strategies Worldwide
Moderators: A. Munck (FR) / A. Mehta (UK)
16:30-16:50 - Introduction - P. Farrell (to include Abstract 30)
16:50-17:00 - Abstract 31: Cystic fibrosis Heelprick among a newbOrn Population In the Netherlands: the CHOPIN-study - A Vernooij-van Langen (NL)
17:00-17:10 - Abstract 38: Implementation of the UK Newborn Screening Programme – K. Southern (UK)
17:10-17:20 - Abstract 32: Cystic Fibrosis (CF) Newborn Screening (NBS) - Comparison of an IRT-PAP with an IRT-DNA based protocol in a German population – O. Sommerburg (DE)
17:20-17:30 - Abstract 52: Genetic aspect of two-year experience in cystic fibrosis newborn screening program in Poland – A. Norek (PL)
17:30-17:40 - Abstract 420: Extensive carrier testing and CF birth prevalence: Evidence for a negative correlation – C. Castellani (IT)
17:40-18:00 - Discussion Time

16:30-18:00 - Workshop 19 - New Insights into Prevention and Eradication of Infection
Moderators: S. Aaron (CA) / G. Chabanon (FR)
16:30-16:45 - Abstract 180: Detection of anaerobic bacteria in bronchoalveolar lavage fluid from paediatric CF patients – M. Tunney (UK)
16:45-17:00 - Abstract 148: Prevention of initial P. aeruginosa infection in children with cystic fibrosis: a multi-centre double-blind randomised controlled trial – G. Tramper-Stranders (NL)
17:00-17:15 - Abstract 151: An aerosol decay model of Pseudomonas aeruginosa survival – I. Clifton (UK)
17:15-17:30 - Abstract 184: Treatment of Non-Tuberculous Mycobacteria in Adults with Cystic Fibrosis – C. Haworth (UK)
17:30-17:45 - Abstract 170: Eradication of methicillin resistant Staphylococcus aureus in cystic fibrosis – M. Kappler (DE)
17:45-18:00 - Abstract 137: Burkholderia cenocepacia: nearing the end? – E. Spencer (UK)

16:30-18:00 - Workshop 20 - Nursing/Psychosocial: Complex Case Presentations
Expert Panel:
A. Gravelle (CA) / K. Colpaert (BE) / M. Kirszenbaum (FR) / G. Ullrich (DE)
16:30-16:44 - Are we able to effectively manage end of life care when the patient wants minimal input? – J. Robinson (UK)
16:44-16:58 - A Dietetic and Psychological Behavioral Approach towards Treating Food Neophobia – E. Landau / L. Peleg-Weiss (IL)
16:58-17:12 - Pain control and palliative care in CF patients end of life – P. Catastini (IT)
17:12-17:26 - The Impact of Chronic illness and Family on Individual Functioning – M. Hammill (AU)
17:26-17:40 - Cystic Fibrosis and pregnancy; managing the reluctant patient – C. Ryder (UK)
17:40-17:54 - Refusal to admit: a child protection issue? – K. Blakeley (UK)        
17:54-18:00 - Best Case presentation award 

20:30 - Conference Dinner

Saturday 13 June 2009

09:00-10:30 - Symposium 16 - GI challenges in CF
Moderators: A. Munck (FR) / J. Walkowiak (PL)
Speakers:
09:00-09:22 - Pancreatitis, CF and genetics - P. Durie (CA)
09:22-09:44 - Enzyme therapy dose and efficacy - J. Sarles (FR)
09:44-10:06 - CFTR and intestinal function - M. Drumm (US)
10:06-10:30 - Does enteropathy in CF really exist? - M. Wilschanski (IL)

09:00-10:30 - Symposium 17 - CF and Innate Immunity
Moderators: G. Döring (DE) / C. Moser (DK)
Speakers:
09:00-09:22 - CFTR and inflammation - A. Edelman (FR)
09:22-09:44 - Toll receptors and CF - M. Chignard (FR)
09:44-10:06 - Developing and sustaining airwary inflammation - S. Randell (US)
10:06-10:30 - Prospect for anti inflammatory therapy - M. Griese (DE)

09:00-10:30 - Symposium 18 - Diagnosis and Management of Rare and New pathogens
Moderators: H. Heijerman (NL) / P. Drevinek (CZ)
Speakers:
09:00-09:22 - Non Tuberculous Mycobacteria - H. Heijerman (NL)
09:22-09:44 - Aspergillus - M. Skov (DK)
09:44-10:06 - Burkholderia cepacia complex - J. Govan (UK)
10:06-10:30 - Less common gram negative microorganisms - N. Høiby (DK)

09:00-10:30 - Symposium 19 - 20 years of CFTR
Moderators: P. Lehn (FR) / F. Becq (FR)
Speakers:
09:00-09:22 - CFTR processing - J. Riordan (US)
09:22-09:44 - CFTR folding - I. Callebaut (FR)
09:44-10:06 - CFTR structure and function - D.N. Sheppard (UK)
10:06-10:30 - CFTR bicarbonate - P. Quinton (US)

09:00-10:30 - Symposium 20 - Fertility and Pregnancy
Moderators: G. Thorpe-Beeston (UK) / S. Madge (UK)
Speakers:
09:00-09:22 - ECFS Consensus guidelines - S. Madge (UK)
09:22-09:44 - Pre-conception planning when, what, and how? - H. Oxley (UK)
09:22-09:44 - Fertility and assisted reproduction - impact on health - D. Hubert (FR)
10:06-10:30 - Managing parenthood with CF - K. Colpaert (BE)

10:30-11:00 - Coffee break

11:00-12:30 - Plenary II - Partnerships for new treatment
Moderators: C. Castellani (IT) / P. Lehn (FR)
Speakers:
How treatment improves quality of life - A. Quittner (US)
Clinical Trials: Priorities and challenges - H. Tiddens (NL)
Patient organisations' contribution to clinical research - F. Dufour (FR)
 
12:30-13:00 - Closing Ceremony

13:30-18:30 - Scientific Committee Meeting - Valencia 2010 

Back to top